Audit of NHS shows only 1% of kidney cancer patients are enrolled in clinical trials
We are pleased to announce the publication of the second [...]
Impact of first-line combination treatment on outcomes of second-line TKI in advanced kidney cancer
There is limited information on the outcomes of patients who [...]
First-line benmelstobart plus anlotinib versus sunitinib in advanced kidney cancer
A new immunotherapy called benmelstobart, which blocks the action of [...]
New immunotherapy for metastatic kidney cancer could help improve outcomes
Researchers from the University of California in Los Angeles (UCLA) [...]
Stereotactic ablative radiotherapy (SABR) for advanced kidney cancer
Stereotactic ablative body radiotherapy (SABR) uses an intense beam of radiation focused [...]
The Yorkshire Kidney Screening Trial
The Yorkshire Kidney Screening Trial is the first study to [...]
Minimally invasive, maximally effective: The rise of Interventional Oncology
Interventional oncology is a type of interventional radiology. It is [...]
Circulating tumour DNA (ctDNA) as a test for kidney cancer
When a tumour grows it 'sheds' small pieces of tumour [...]
Comparison of real-world outcomes from combination therapies for advanced kidney cancer
Direct comparisons of combination treatments for previously untreated, advanced kidney [...]
Pembrolizumab plus axitinib shows sustained benefit in advanced kidney cancer
The final long-term follow-up data from the phase 3 KEYNOTE-426 [...]
